Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
STUDY DESIGN: An experimental study to investigate the activation of Src/Stat3 pathways in chordomas and blockage of this pathway as a potential strategy for chordoma treatment. OBJECTIVE: To investigate the activation of Src/Stat3 pathway in chordomas cells and to determine the efficiency of inhibiting this pathway by 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic acid-methyl ester (CDDO-Me) as a potential chemotherapeutic agent for chordoma treatment. SUMMARY OF BACKGROUND DATA: The advent of molecularly targeted therapies has raised interest for their use in the treatment of chordomas. Unfortunately, the current understanding of molecular markers in chordomas is limited. Constitutive activation of Stat3 is a common finding in a wide spectrum of human cancers. The function of Stat3 pathway in chordomas has not been elucidated. METHODS: The expression of key components of the Src/Stat3 signaling cascade was evaluated by Western blot in chordoma tissues and chordoma cell lines. The effects of CDDO-Me on chordoma cell growth were evaluated in these chordoma cell lines by MTT assay. The expression of key components of the Src/Stat3 signaling cascade and poly (ADP-ribose) polymerase cleavage in these CDDO-Me treated cells were analyzed by Western blot and immunofluorescence. Furthermore, the synergistic effect of CDDO-Me on cisplatin and doxorubicin-induced cytotoxicity was evaluated by MTT. Finally, chordoma cells were grown in a 3-dimensional (3D) culture and treated with CDDO-Me. RESULTS: The key components of the Src/Stat3 signaling cascade, including Stat3, pStat3, Src, pSrc, Bcl-xL, and Myeloid Cell Leukemia-1, were all highly expressed in chordomas. Expression of the key components of the Src/Stat3 signaling cascade was inhibited in chordoma cells after treatment with CDDO-Me. The growth of chordoma cells was inhibited and apoptosis associated poly (ADP-ribose) polymerase cleavage was detected after treatment with CDDO-Me. Additionally, CDDO-Me has a synergistic effect on cisplatin or doxorubicin-induced chordoma cell death (P < 0.001). Finally, expression of pSrc and pStat3 and chordoma cell growth was inhibited by treatment of CDDO-Me using 3D culture. CONCLUSION: The Src/Stat3 signaling pathway was activated in chordomas. Blockage of Src/Stat3 pathway by CDDO-Me is a potential strategy for chordoma treatment and may be focus for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 3×
“cells to the loss of Stat3 function,(28) has driven the effort to identify molecules able to inhibit Stat3 as a strategy for both prevention and treatment of various cancers.(15) Aberrant Stat3 activation may not only gain a growth advantage but also confer resistance to radiation and chemotherapies based on apoptotic…”
BackgroundCatlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
The role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · cited 3×
“The oncogenic significance of activated Stat3 is due to their effects on numerous parameters of the development and progression of malignancy, such as apoptosis, cell proliferation, angiogenesis, and immune system evasion.(14) Its role in tumorigenesis is mediated through the expression of various survival genes.”
BackgroundTranscription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · cited 1×
“Stat3 is a cytoplasmic transcription factor, which is activated by cytokines and growth factor receptors, after its phosphorylation on tyrosine 705 by tyrosine kinases of the Janus tyrosine kinases (JAKs) and/or Src family, it dimerises and enters the nucleus where it induces the expression of target genes.(12,14,15)…”
BackgroundTriterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Ahmad, R., Raina, D., Meyer, C., & Kufe, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3036 · Cited by 120 · cited 7×
“These compounds are under study in phase I and II clinical trials for the treatment of patients with hematologic malignancies and solid tumors.30,31 Treatment with CDDO-Me significantly decreases the levels of Stat3, JAK1, JAK2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activa…”
BackgroundInfluential
Cited by
Chordoma: current concepts, management, and future directions
Walcott, B. P., Nahed, B. V., Mohyeldin, A., Coumans, J.-V., Kahle, K. T., & Ferreira, M. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70337-0 · Cited by 769
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
Huang, S., Chen, M., Shen, Y., Shen, W., Guo, H., Gao, Q., & Zou, X. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.011 · Cited by 94
Personalized chordoma organoids for drug discovery studies
Al Shihabi, A., Davarifar, A., Nguyen, H. T. L., Tavanaie, N., Nelson, S. D., Yanagawa, J., Federman, N., Bernthal, N., Hornicek, F., & Soragni, A. (2022) · Science Advances · doi:10.1126/sciadv.abl3674 · Cited by 75
Self-citationUmbaugh, C. S., Groth, M., Erkut, C., Lee, K.-S., Marinho, J., Linder, S., Iser, F., Kapp, J. N., Schroeter, P., Dolaner, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2796 · Cited by 6
Metadata
- Authors
- Yang, C., Hornicek, F. J., Wood, K. B., Schwab, J. H., Choy, E., Mankin, H., & Duan, Z.
- Venue
- Spine
- Published
- 2010-08
- Volume
- 35
- Issue
- 18
- Pages
- 1668-1675
- ISSN
- 0362-2436 (ISSN-L)
- OpenAlex
- W1975372065
- Cited by
- 42
- References
- 7
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.